Cite
HARVARD Citation
Dioun, S. et al. (2023). Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study. BJOG. pp. 214-221. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dioun, S. et al. (2023). Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study. BJOG. pp. 214-221. [Online].